Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy

Malika Gupta, Kashif Jafri, Rebecca Sharim, Susanna Silverman, Sayantani B. Sindher, Anupama Shahane, Mildred Kwan

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


The use of biologics in the treatment of autoimmune disease, cancer, and other immune conditions has revolutionized medical care in these areas. However, there are drawbacks to the use of these medications including increased susceptibility to opportunistic infections. One unforeseen risk once opportunistic infection has occurred with biologic use is the onset of immune reconstitution inflammatory syndrome (IRIS) upon drug withdrawal. Although originally described in human immunodeficiency virus (HIV) patients receiving highly active antiretroviral therapy, it has become clear that IRIS may occur when recovery of immune function follows opportunistic infection in the setting of previous immune compromise/suppression. In this review, we draw attention to this potential pitfall on the use of biologic drugs.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCurrent Allergy and Asthma Reports
Issue number2
StatePublished - Feb 2015
Externally publishedYes


  • Autoimmunity
  • Biologics
  • Immune reconstitution inflammatory syndrome
  • JAK inhibitors
  • Monoclonal antibodies
  • Progressive multifocal leukoencephalopathy


Dive into the research topics of 'Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy'. Together they form a unique fingerprint.

Cite this